Page URL: https://www.bionews.org.uk/rachelsiden

Rachel Siden

Rachel Siden is a Volunteer Writer at BioNews. She originally studied Philosophy at the University of Massachusetts, Amherst and went on to obtain an MA in Bioethics and Society from King's College London, where her research focused on the ethics of compulsory vaccine laws in the USA. Her current research interests are ethical issues surrounding genome editing and genomic medicine, which she writes about on her blog The CRISPR Drawer.


BioNews Review articles written by Rachel Siden:
Page 1 of 1
Book Review: Experiments in Democracy - Human Embryo Research and the Politics of Bioethics
15 May 2017 - by Rachel Siden
Experiments in Democracy recounts the history of human embryo research debates in the United States while exploring how the democratic formulation of policy is impacted by complex relationships between science, bioethics, and the public... [Read More]
Podcast Review: Naked Genetics - All Human Life Is Here
23 January 2017 - by Rachel Siden
In this podcast, Professor Magdalena Zernicka-Goetz and Sarah Norcross discuss the current UK ban on researching human embryos in the lab for longer than 14 days... [Read More]
Podcast Review: Ethics and Genetics – Opening the Book of Life
14 November 2016 - by Rachel Siden
This podcast from the Guardian's Science Weekly series is a good introduction to the ethical questions surrounding genetic technologies... [Read More]
Theatre Review: Half of Me
8 August 2016 - by Rachel Siden
Half of Me is a play aimed at a young audience, and tells the story of children born through Assisted Reproductive Technology (ART)... [Read More]

BioNews News articles written by Rachel Siden:
Page 1 of 2
HFEA to issue regulations on IVF add-ons
16 July 2018 - by Rachel Siden
The Human Fertilisation and Embryology Authority will require fertility clinics to give patients full information about any IVF 'add-on' services being offered to them... [Read More]
Canadian scientists call for end to criminal ban on germline genome-editing
13 November 2017 - by Rachel Siden
Members of Canada's Stem Cell Network have called for the country to re-examine its laws banning genome editing research on the human germline... [Read More]
Australian insurance inquiry to consider genetic discrimination
29 August 2017 - by Rachel Siden
A parliamentary inquiry in Australia is examining the impact of life insurance discrimination based on genetic test results... [Read More]
NgAgo is a no-go
7 August 2017 - by Rachel Siden
The original paper promoting a new genome editing technology known as Natronobacterium gregoryi Argonaute (NgAgo) has been retracted... [Read More]
China sides with Berkeley on CRISPR patent
3 July 2017 - by Rachel Siden
China's State Intellectual Property Office has granted the University of California a patent on CRISPR-Cas9 gene editing technology in the country.
ACMG recommends caution on genome editing
6 February 2017 - by Rachel Siden
The American College of Medical Genetics and Genomics has published a statement recommending caution over the clinical application of genome editing... [Read More]
US Senate passes regenerative medicine act
12 December 2016 - by Rachel Siden
Stem cell therapies could be granted accelerated approval by the US Food and Drug Administration as part of a new bill passed by the Senate last week... [Read More]
Disgraced stem cell entrepreneur may be offering therapies abroad
21 November 2016 - by Rachel Siden
Italian prosecutors are investigating whether discredited stem-cell entrepreneur Davide Vannoni is continuing to offer his unproven therapies in eastern Europe... [Read More]
Nuffield Council publishes preliminary ethical review of genome editing
3 October 2016 - by Rachel Siden
Use of genome editing in human reproduction requires 'urgent ethical scrutiny', according to a report published by the Nuffield Council on Bioethics... [Read More]
Chinese scientists to begin first human CRISPR trial
25 July 2016 - by Rachel Siden
Chinese scientists plan to start the first-ever clinical trial of CRISPR genome-editing technology in humans – on patients with lung cancer – this August... [Read More]